Publications en collaboration avec des chercheurs de Hospital Clinic Barcelona (17)

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

  3. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

    Journal of Neuro-Oncology

2022

  1. Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial

    Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661

2021

  1. SEOM clinical guideline for management of adult medulloblastoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947

2020

  1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

    Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861

2018

  1. A phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii372

  2. Correction to: SEOM clinical guidelines for anaplastic gliomas (2017) (Clinical and Translational Oncology, (2018), 20, 1, (16-21), 10.1007/s12094-017-1762-7)

    Clinical and Translational Oncology

  3. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients

    Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537

  4. SEOM clinical guideline in nasopharynx cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 84-88

  5. SEOM clinical guidelines for anaplastic gliomas (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 16-21

2015

  1. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273

2014

  1. Capillary Electrophoresis Analysis of Conventional Splicing Assays: IARC Analytical and Clinical Classification of 31 BRCA2 Genetic Variants

    Human Mutation, Vol. 35, Núm. 1, pp. 53-57

  2. Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

    Journal of Neuro-Oncology, Vol. 116, Núm. 2, pp. 413-419

  3. Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y]

    Journal of Neuro-Oncology

  4. Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

    Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279

2012

  1. Need to implement a coordinated and multidisciplinary care in the Spanish population at increased risk for colorectal cancer

    Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 333-337